LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs

 LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs

LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs

Shots:

  • Zymeworks to get $5M upfront plus research funding payments from LEO, $231M as milestone to commercialize first candidate & up to $244M for the second candidate along with 20% US sales royalties
  • Zymeworks retains rights to develop non-dermatology molecule using this cytokine receptor pathway where LEO will receive milestone payments and single digit royalties
  • LEO gets WW rights to research, develop & commercialize two bispecific Abs using Zymeworks’ Azymetric and EFECT platforms focused on dermatology
  • Azymetric platform helps in transforming monospecific Abs into bispecific Abs, enabling them to bind multiple targets. The EFECT platform is a collection Abs Fc modifications used in modulating Ab-mediated immune response

Click here to read full press release/ article | Ref: LEO pharma | Image: Appadvice

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post